The invention, provides a method and a device for delivery of foam to a target site of a respiratory system of a subject.

A nebulized medication delivery method includes: providing an interventional catheter, nebulizing a fluid containing a therapeutic substance through the interventional catheter and delivering nebulized fluid to a lesion site; wherein the fluid includes a liquid-phase fluid and a gas-phase fluid, and at least one of the liquid-phase fluid and the gas-phase fluid carries the therapeutic substance.

A method and device to improve lung function in a patient having restricted ventilation. The device may include an implantable airway bypass device that relieves trapped air. The method may include a treatment procedure that minimizes irritation of tissue to control healing processes.

One aspect of the invention relates to a hydrogel comprising a non-natural polymer comprising a plurality of pendant nucleophilic groups and a crosslinker comprising at least two pendant electrophilic groups. Another aspect of the invention relates to a hydrogel comprising a non-natural polymer comprising a plurality of pendant electrophilic groups and a crosslinker comprising at least two pendant nucleophilic groups. Yet another aspect of the invention relates to a method for reducing lung volume in a patient comprising the step of administering a hydrogel composition as described herein. Further, hydrogels of the invention may be used to achieve pleurodesis, seal brochopleural fistulas, seal an air leak in a lung, achieve hemostasis, tissue sealing (e.g., blood vessels, internal organs), or any combination thereof. In certain embodiments, the compositions and methods described herein are intended for use in the treatment of patients with emphysema.

A medical system may include an elongate member having a proximal end and a distal end, the elongate member being movable between a collapsed configuration and an expanded configuration, and a first therapeutic agent configured to treat a condition of the lung.

Methods are provided for protecting against ventilation-induced lung injury by promoting equitable liquid distribution in a lung with alveolar flooding, in which flooded and aerated alveoli are interspersed. Since ventilation injuriously over-expands aerated alveoli adjacent to flooded alveoli and a pressure barrier is responsible for trapping liquid in discrete alveoli, the present invention provides various means for overcoming the pressure barrier to, in turn, promote equitable redistribution of flooding liquid amongst alveoli, reduce the number of aerated alveoli located adjacent to flooded alveoli and reduce ventilation injury of the lung. These means of overcoming the pressure barrier include: (i) use of accelerated deflation during mechanical ventilation; and ii) high frequency (>50 Hz) vibration of the lung.

Various embodiments disclosed relate to drug-coated balloon catheters for treating, preventing, or reducing the recurrence of a stricture and/or cancer, or for treating benign prostatic hyperplasia (BPH), in a non-vascular body lumen and methods of using the same. A drug-coated balloon catheter for delivering a therapeutic agent to a target site of a body lumen stricture includes an elongated balloon having a main diameter. The balloon catheter includes a coating layer overlying an exterior surface of the balloon. The coating layer includes one or more water-soluble additives and an initial drug load of a therapeutic agent. In some embodiments, the balloon catheter includes a length-control mechanism which stretches and elongates the balloon when it is in a deflated state, giving the balloon a smaller cross-sectional deflated profile for tracking through the body lumen and for removal after treatment.

A system includes a chest tube drainage system comprising a first chamber in fluid communication with a port connectable to a chest tube, a second chamber in fluid communication with a port connectable to a suction device, and a fluid seal connected to and disposed between the first chamber and the second chamber. The system also includes one or more gas sensors attached to the chest tube drainage system, the one or more gas sensors configured to detect at least one of gaseous carbon dioxide and gaseous oxygen, a controller connected to the one or more gas sensors, and at least one indicator coupled to the controller. The controller is configured to determine if a threshold level of carbon dioxide is exceeded, and to activate the at least one indicator if the threshold level of carbon dioxide is not exceeded.

The invention has as its object the provision of a medicine capable of reducing a volume of emphysema-suffering pulmonary alveoli or alveolar sacs by means of a respiratory region volume inhibitor containing a coating film formation as a main component and capable of forming a coating film in a respiratory region, characterized by being used in such a way that the coating film-forming component is administered to an emphysema-suffering pulmonary alveolar parenchyma in a human-respiratory region in an amount of 0.004 to 200 g/application, preferably 0.07 to 20 g/application and more preferably 0.5 to 5 g/application on each occasion.

A single step body insertion device contains a Veress needle 10 which penetrates the skin surface and relevant tissue layers to reach fluid and/or gases that need to be removed from the body. The device comprises a cannula shaft 2 with a tapered distal tip 3 and a proximal hub 4 with a side port 7 housing a one way low pressure cracking valve 8. The cannula shaft is of a polymeric material which is flexible and kink resistant. The device is used for the management of conditions such as pneumothoraxes and pleural effusions as well as other conditions that require release of fluid and/or gas from the body.